Lipton, Jeffrey H.
Brümmendorf, Tim H.
Sweet, Kendra
Apperley, Jane F.
Cortes, Jorge E.
Article History
Received: 1 February 2024
Accepted: 11 June 2024
First Online: 18 July 2024
Declarations
:
: Not applicable.
: Not applicable.
: • Jeffrey Lipton: consultant for Bristol-Myers Squibb, Novartis, Pfizer, and Takeda; research funding from Bristol Myers Squibb, Novartis, Pfizer, and Takeda; honoraria from Bristol Myers Squibb, Novartis, Incyte, Pfizer and Takeda.• Tim H Brümmendorf: consultant for Janssen, Merck, Novartis, Pfizer, and research support from Novartis and Pfizer.• Kendra Sweet: advisory board member/consulting for Gilead, Bristol Myers Squibb, Astellas, BerGenBio, Arog, Novartis, Curis, Pfizer, Mablytics, Daiichi Sankyo, Jazz, Nkarta; research funding from Incyte, Jazz.• Jane F Apperley: advisory board member for Ariad/Incyte and Novartis; speaker at satellite symposia for Ariad/Incyte and Novartis; research funding from Ariad/Incyte and Pfizer.• Jorge E Cortes: consultant for Amphivena Therapeutics, Astellas Pharma, Bio-Path Holdings Inc, BiolineRx, Bristol Myers Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Pfizer, and Takeda; research funding from Astellas Pharma, Bristol Myers Squibb, Daiichi Sankyo, Immunogen, Jazz Pharmaceuticals, Merus, Novartis, Pfizer, Sun Pharma, Takeda, Tolero Pharmaceuticals and Tovagene.